Susceptible Gram-negative infections, Susceptible staphylococcal infections
Adult: 3 mg/kg daily in 2-3 divided doses. May also be given as IV infusion, if needed.
Topical/Cutaneous
Pyoderma
Adult: As 0.1% cream: Apply onto the affected area(s) bid.
Indications and Dosage
Intramuscular
Susceptible Gram-negative infections, Susceptible staphylococcal infections Adult: 3 mg/kg daily in 2-3 divided doses. May also be given as IV infusion, if needed. Topical/Cutaneous Pyoderma Adult: As 0.1% cream: Apply onto the affected area(s) bid.
|
Renal Impairment
Intramuscular:
May need to adjust maintenance doses and/or dosing intervals. |
Contraindications
Hypersensitivity.
|
Special Precautions
Renal or liver impairment, myasthenia gravis, parkinsonism, dehydration, hypotension, pregnancy, lactation.
|
Adverse Reactions
Ototoxicity, nephrotoxicity, neurotoxicity (peripheral neuropathy, confusion, lethargy, hallucination, convulsion and mental depression, occasional respiratory depression), rarely hypersensitivity reaction.
Potentially Fatal: Acute renal failure especially in combination with other nephrotoxic drugs. |
Drug Interactions
Plasma levels increased by indometacin. Antihistamines (H1-receptor blocker) may mask early signs of ototoxicity. Incompatible with some β-lactam antibiotics.
Potentially Fatal: Potentiates nephrotoxicity produced by other nephrotoxic drugs including other aminoglycosides, vancomycin and some cephalosporins. Potentiates ototoxicity produced by other aminoglycosides, ethacrynic acid. Ototoxicity potentiated by furosemide. |
Action
Description: Sisomicin binds to 30s and 50s ribosomal subunits of susceptible bacteria disrupting protein synthesis, thus rendering the bacterial cell membrane defective.
|
MIMS Class
|